

# John A Petros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11065460/publications.pdf>

Version: 2024-02-01

47  
papers

7,021  
citations

236612

25  
h-index

264894

42  
g-index

47  
all docs

47  
docs citations

47  
times ranked

8107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer. <i>New England Journal of Medicine</i> , 1991, 324, 1156-1161.	13.9	2,106
2	In vivo molecular and cellular imaging with quantum dots. <i>Current Opinion in Biotechnology</i> , 2005, 16, 63-72.	3.3	1,131
3	mtDNA mutations increase tumorigenicity in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 719-724.	3.3	763
4	Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. <i>Nature Protocols</i> , 2007, 2, 1152-1165.	5.5	472
5	Increased Nox1 and hydrogen peroxide in prostate cancer. <i>Prostate</i> , 2005, 62, 200-207.	1.2	309
6	Expression Profiling of Renal Epithelial Neoplasms. <i>American Journal of Pathology</i> , 2001, 158, 1639-1651.	1.9	300
7	Effects of Rectal Examination, Prostatic Massage, Ultrasonography and Needle Biopsy on Serum Prostate Specific Antigen Levels. <i>Journal of Urology</i> , 1992, 147, 810-814.	0.2	172
8	Human $\beta$ -Defensin-1, a Potential Chromosome 8p Tumor Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell Carcinoma. <i>Cancer Research</i> , 2006, 66, 8542-8549.	0.4	157
9	Molecular Mapping of Tumor Heterogeneity on Clinical Tissue Specimens with Multiplexed Quantum Dots. <i>ACS Nano</i> , 2010, 4, 2755-2765.	7.3	143
10	Novel mitochondrial DNA deletion found in a renal cell carcinoma. , 1996, 15, 95-101.		140
11	Molecular Classification of Renal Tumors by Gene Expression Profiling. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 206-218.	1.2	130
12	Beta Defensin-1, Parvalbumin, and Vimentin. <i>American Journal of Surgical Pathology</i> , 2003, 27, 199-205.	2.1	111
13	Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence. <i>Cancer Research</i> , 2014, 74, 3228-3237.	0.4	111
14	Cancer-Specific Loss of $\beta$ -Defensin 1 in Renal and Prostatic Carcinomas. <i>Laboratory Investigation</i> , 2003, 83, 501-505.	1.7	110
15	Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. <i>Cancer Research</i> , 2006, 66, 9519-9526.	0.4	94
16	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 511-518.	1.1	70
17	Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. <i>Prostate</i> , 2009, 69, 1-11.	1.2	61
18	Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 227-234.	1.1	57

#	ARTICLE	IF	CITATIONS
19	Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. <i>Prostate</i> , 2001, 48, 305-315.	1.2	56
20	Nox1 Expression Determines Cellular Reactive Oxygen and Modulates c-fos-Induced Growth Factor, Interleukin-8, and Cav-1. <i>American Journal of Pathology</i> , 2007, 171, 2021-2032.	1.9	51
21	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. <i>Bone</i> , 2015, 78, 81-86.	1.4	44
22	An Inherited Heteroplasmic Mutation in Mitochondrial Gene COI in a Patient with Prostate Cancer Alters Reactive Oxygen, Reactive Nitrogen and Proliferation. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	43
23	Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics. <i>Urology</i> , 2018, 113, 40-44.	0.5	37
24	Novel Synthesis and Biological Evaluation of Enigmols as Therapeutic Agents for Treating Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 438-443.	1.3	33
25	Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. <i>Prostate</i> , 2009, 69, 956-960.	1.2	32
26	Preoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy. <i>Journal of Proteome Research</i> , 2019, 18, 1316-1327.	1.8	30
27	Mitochondrial genotype and breast cancer predisposition. <i>Oncology Reports</i> , 2010, 24, 1521-34.	1.2	26
28	A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer. <i>Prostate</i> , 2015, 75, 1916-1925.	1.2	23
29	Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth. <i>Oncotarget</i> , 2014, 5, 9911-9929.	0.8	22
30	Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics. <i>Journal of Proteome Research</i> , 2021, 20, 3629-3641.	1.8	22
31	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018, 10, 379.	1.7	21
32	Current trends in molecular classification of adult renal tumors. <i>Urology</i> , 2006, 67, 873-880.	0.5	20
33	Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 537-542.	1.3	20
34	Mitochondrial Cytochrome c Oxidase Subunit 1 Sequence Variation in Prostate Cancer. <i>Scientifica</i> , 2012, 2012, 1-7.	0.6	18
35	The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression. <i>Translational Oncology</i> , 2020, 13, 100751.	1.7	17
36	Aquaporin-1 Protein Levels Elevated in Fresh Urine of Renal Cell Carcinoma Patients: Potential Use for Screening and Classification of Incidental Renal Lesions. <i>Disease Markers</i> , 2014, 2014, 1-6.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Discovery and mechanisms of host defense to oncogenesis: targeting the $\beta$ -defensin-1 peptide as a natural tumor inhibitor. <i>Cancer Biology and Therapy</i> , 2019, 20, 774-786.	1.5	12
38	Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. <i>Cancers</i> , 2020, 12, 3095.	1.7	10
39	Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage. <i>Cancers</i> , 2021, 13, 6253.	1.7	10
40	Automated sequencing of complete mitochondrial genomes from laser-capture microdissected samples. <i>BioTechniques</i> , 2003, 35, 606-612.	0.8	7
41	Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis. <i>International Journal of Urology</i> , 2020, 27, 790-797.	0.5	7
42	von Hippel-Lindau Exonic Methylation Analysis Using MALDI-TOF Mass Spectrometry. <i>Journal of Urology</i> , 2014, 192, 1528-1533.	0.2	5
43	Perioperative hormonal therapy in locally advanced adenocarcinoma of the prostate. <i>Cancer</i> , 1995, 75, 1969-1971.	2.0	3
44	Prostate Cancer Bone Colonization: Osteomimicry in the Bone Niche. , 2010, , 157-166.		1
45	Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy. <i>FASEB Journal</i> , 2011, 25, .	0.2	0
46	RNAseq Analysis of FFPE Radical Prostatectomy Specimens Identifies Predictors of Biochemical Recurrence. <i>FASEB Journal</i> , 2013, 27, 471.8.	0.2	0
47	Mitochondrial DNA mutations in prostate cancer bone metastases. <i>Journal of Nature and Science</i> , 2015, 1, .	1.1	0